Clonal chromosomal abnormalities in CD34+/CD38- hematopoietic cells from cytogenetically normal chronic myeloid leukemia patients with a complete cytogenetic response to tyrosine kinase inhibitors.
Oregon Health & Science University Knight Cancer Institute, Portland, Oregon, USA.
Thomas
T
Bumm
Oregon Health & Science University Knight Cancer Institute, Portland, Oregon, USA.
Jutta
J
Deininger
Department of Molecular and Medical Genetics, Oregon Health & Science University, Portland, Oregon, USA.
Amy Hanlon
AH
Newell
Department of Molecular and Medical Genetics, Oregon Health & Science University, Portland, Oregon, USA.
Helen
H
Lawce
Department of Molecular and Medical Genetics, Oregon Health & Science University, Portland, Oregon, USA.
Susan
S
Olson
Oregon Health & Science University Knight Cancer Institute, Portland, Oregon, USA.
Michael
M
Mauro
Oregon Health & Science University Knight Cancer Institute, Portland, Oregon, USA.
Brian
B
Druker
Oregon Health & Science University Knight Cancer Institute, Portland, Oregon, USA.
Michael
M
Deininger
D051997:ADP-ribosyl Cyclase 1 / Q000032:analysis*; D000368:Aged; D018952:Antigens, CD34 / Q000032:analysis*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002469:Cell Separation; D002869:Chromosome Aberrations; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D017404:In Situ Hybridization, Fluorescence; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy / Q000235:genetics* / Q000276:immunology / Q000473:pathology; D008297:Male; D008875:Middle Aged; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D016896:Treatment Outcome
D018952:Antigens, CD34; D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D011505:Protein-Tyrosine Kinases; D051997:ADP-ribosyl Cyclase 1